CClinicalTrials.gg
CompletedNCT06001840Updated Feb 10, 2026Results posted

Promotion and Mitigation Factors Leading to Illegal Tobacco Purchases

An interventional study of Promotion factors and Mitigation strategies in Cigarette Smoking and Nicotine Vaping, sponsored by Virginia Polytechnic Institute and State University. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Virginia Polytechnic Institute and State University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

This study will investigate the effects of promotion factors and mitigation strategies on legal and illegal tobacco purchases for different tobacco-user types.

Read the detailed description

In the present study, we propose to examine some promotion factors and mitigation strategies and how they impact tobacco product legal and illegal purchases. Specifically, we have developed an Illegal Experimental Tobacco Marketplace (iETM). The iETM permits us to identify the number, type, and characteristics of tobacco users who would seek illegal tobacco products and the conditions that would induce them to seek that option. The critical questions we seek to answer are whether changes in product standards and availability will engender illegal tobacco purchasing as a function of tobacco user type (e.g., exclusive combustible product users, and dual cigarette/NVP users). Understanding the user types and the relevant conditions will inform greater tailoring of policy to diminish consumer interest in an illegal market.

02

Conditions studied

  • Cigarette Smoking
  • Nicotine Vaping
03

In context

Cigarette Smoking

114 studies on the registry are indexed under Cigarette Smoking; 59 are open to participants now.

This study's enrollment of 65 is below the median of 100 across 101 interventional studies indexed under Cigarette Smoking.

Browse Cigarette Smoking studies →

Lead sponsor

Virginia Polytechnic Institute and State University is the lead sponsor of 124 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Provide informed consent
  • Be at least 21 years of age or older
  • Provide a breath sample for measuring carbon monoxide (CO ≥ 8 ppm)
  • Stable tobacco use patterns for at least two months

For exclusive cigarette smokers:

  • Smoke at least 10 cigarettes daily and do not use NVPs regularly (no more than 9 times in the last month).
  • For dual cigarette/NVP users:
  • Smoke at least 10 cigarettes daily and use NVPs at least 3 times in a week (report use of closed nicotine salt system)

Exclusion criteria

Exclusion criteria:

  • Have plans to move out of the area
  • Have a serious or unstable physical or mental health condition
  • Taking a tobacco cessation medication or medication that interferes with nicotine metabolism, motivation or reinforcement
  • Report concrete, immediate plans to alter/quit using their usual nicotine products at the beginning of the study
  • Being pregnant or lactating
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Experimental: Exclusive cigarette smokers

    Exclusive cigarette smokers will be recruited and will be exposed to all of the conditions described in the intervention section.

    Behavioral: Promotion factors · Behavioral: Mitigation strategies

  • Experimental
    Experimental: Dual cigarette/ nicotine vaping product users

    Dual cigarette and nicotine vaping product users will be recruited and will be exposed to all of the conditions described in the intervention section

    Behavioral: Promotion factors · Behavioral: Mitigation strategies

Interventions

  • BehavioralPromotion factors

    In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only VLNCs in the LETM and preferred cigarettes will be available in the iETM.

  • BehavioralMitigation strategies

    Penalties: Penalties will be presented as a 60% chance of getting caught making illegal purchases. The consequences of illegal purchases include not receiving any study products from the ETM if they were caught and randomly drew that trial.

06

What researchers measure

Primary outcomes

  1. Percent Budget Spent on Illegal Cigarettes Across Policy Conditions

    The study has 4 policy conditions with combinations of promotion strategy (VLNC standard) and mitigation strategy (penalties), and each combination: No Policy, Penalty only, VLNC only, and Penalty + VLNC. The average percentage of the budget spent on illegal cigarettes across all trials was calculated for each policy scenario.

    Time frame: 1 day

  2. Percent Budget Spent on Legal Cigarettes Across Policy Conditions

    The study has 4 policy conditions with combinations of promotion strategy (VLNC standard) and mitigation strategy (penalties), and each combination: No Policy, Penalty only, VLNC only, and Penalty + VLNC. The average percentage of the budget spent on legal cigarettes across all trials was calculated for each policy scenario.

    Time frame: 1 day

  3. Percent Budget Spent on E-cigarettes Across Policy Conditions

    The study has 4 policy conditions with combinations of promotion strategy (VLNC standard) and mitigation strategy (penalties), and each combination: No Policy, Penalty only, VLNC only, and Penalty + VLNC. The average percentage of the budget spent on e-cigarettes across all trials was calculated for each policy scenario.

    Time frame: 1 day

  4. Percent Budget Spent on Nicotine Replacement Therapy Across Policy Conditions

    The study has 4 policy conditions with combinations of promotion strategy (VLNC standard) and mitigation strategy (penalties), and each combination: No Policy, Penalty only, VLNC only, and Penalty + VLNC. The average percentage of the budget spent on nicotine replacement theray across all trials was calculated for each policy scenario.

    Time frame: 1 day

  5. Percent Budget Spent on Oral Nicotine/Tobacco Across Policy Conditions

    The study has 4 policy conditions with combinations of promotion strategy (VLNC standard) and mitigation strategy (penalties), and each combination: No Policy, Penalty only, VLNC only, and Penalty + VLNC. The average percentage of the budget spent on oral nicotine/tobacco across all trials was calculated for each policy scenario.

    Time frame: 1 day

07

Results

Posted Feb 10, 2026

Participant flow

Participant flow — Overall Study
MilestoneExperimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product Users
Started3332
No policy2726
Penalty only3129
Vlnc only2726
Penalty + vlnc3129
Completed2726
Not completed66
Withdrew: Lost to follow-up44
Withdrew: Withdrawal by subject02
Withdrew: Screen fail20

Outcome measures

PrimaryPercent Budget Spent on Illegal Cigarettes Across Policy Conditions

The study has 4 policy conditions with combinations of promotion strategy (VLNC standard) and mitigation strategy (penalties), and each combination: No Policy, Penalty only, VLNC only, and Penalty + VLNC. The average percentage of the budget spent on illegal cigarettes across all trials was calculated for each policy scenario.

Time frame:
1 day
Reported as:
Mean · percentage of budget spent
Percent Budget Spent on Illegal Cigarettes Across Policy Conditions
percentage of budget spentExperimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product Users
No Policy40.78 ± 4.0438.41 ± 3.63
Penalty only12.14 ± 2.669.64 ± 2.32
VLNC only71.20 ± 3.4265.18 ± 2.84
Penalty + VLNC26.31 ± 3.4720.94 ± 3.09
PrimaryPercent Budget Spent on Legal Cigarettes Across Policy Conditions

The study has 4 policy conditions with combinations of promotion strategy (VLNC standard) and mitigation strategy (penalties), and each combination: No Policy, Penalty only, VLNC only, and Penalty + VLNC. The average percentage of the budget spent on legal cigarettes across all trials was calculated for each policy scenario.

Time frame:
1 day
Reported as:
Mean · percentage of budget spent
Percent Budget Spent on Legal Cigarettes Across Policy Conditions
percentage of budget spentExperimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product Users
No Policy37.97 ± 3.7329.72 ± 3.28
Penalty only57.30 ± 3.5947.73 ± 3.30
VLNC only4.32 ± 1.310.89 ± 0.37
Penalty + VLNC19.71 ± 2.849.69 ± 2.06
PrimaryPercent Budget Spent on E-cigarettes Across Policy Conditions

The study has 4 policy conditions with combinations of promotion strategy (VLNC standard) and mitigation strategy (penalties), and each combination: No Policy, Penalty only, VLNC only, and Penalty + VLNC. The average percentage of the budget spent on e-cigarettes across all trials was calculated for each policy scenario.

Time frame:
1 day
Reported as:
Mean · percentage of budget spent
Percent Budget Spent on E-cigarettes Across Policy Conditions
percentage of budget spentExperimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product Users
No Policy10.01 ± 1.4823.06 ± 2.27
Penalty only20.16 ± 2.5627.15 ± 2.41
VLNC only11.49 ± 1.7124.06 ± 2.39
Penalty + VLNC37.63 ± 3.1246.51 ± 3.16
PrimaryPercent Budget Spent on Nicotine Replacement Therapy Across Policy Conditions

The study has 4 policy conditions with combinations of promotion strategy (VLNC standard) and mitigation strategy (penalties), and each combination: No Policy, Penalty only, VLNC only, and Penalty + VLNC. The average percentage of the budget spent on nicotine replacement theray across all trials was calculated for each policy scenario.

Time frame:
1 day
Reported as:
Mean · percentage of budget spent
Percent Budget Spent on Nicotine Replacement Therapy Across Policy Conditions
percentage of budget spentExperimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product Users
No Policy2.00 ± 0.443.67 ± 0.86
Penalty only3.11 ± 0.704.56 ± 0.91
VLNC only3.46 ± 0.944.38 ± 1.10
Penalty + VLNC8.71 ± 1.416.89 ± 1.08
PrimaryPercent Budget Spent on Oral Nicotine/Tobacco Across Policy Conditions

The study has 4 policy conditions with combinations of promotion strategy (VLNC standard) and mitigation strategy (penalties), and each combination: No Policy, Penalty only, VLNC only, and Penalty + VLNC. The average percentage of the budget spent on oral nicotine/tobacco across all trials was calculated for each policy scenario.

Time frame:
1 day
Reported as:
Mean · percentage of budget spent
Percent Budget Spent on Oral Nicotine/Tobacco Across Policy Conditions
percentage of budget spentExperimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product Users
No Policy0.85 ± 0.400.12 ± 0.05
Penalty only0.69 ± 0.320.89 ± 0.63
VLNC only1.08 ± 0.500.21 ± 0.09
Penalty + VLNC0.71 ± 0.310.37 ± 0.11

Adverse events

Collected over 9 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Exclusive Cigarette Smokers0/27 (0%)0/27 (0%)0/27 (0%)
Experimental: Dual Cigarette/ Nicotine Vaping Product Users0/26 (0%)0/26 (0%)0/26 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Experimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product UsersTotal
Mean44.74 ± 9.0243.15 ± 8.0443.94 ± 8.53
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product UsersTotal
Female161430
Male111223
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product UsersTotal
Hispanic or Latino011
Not Hispanic or Latino272552
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product UsersTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American6713
White181836
More than one race213
Unknown or Not Reported000
Household Income
Household Income(Participants)Experimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product UsersTotal
Less than $19,000181836
$20,000-$39,999459
$40,000-$64,999134
$65,000-$99,999202
$100,000-$154,999202
Greater than $155,000000
Education
Education(Participants)Experimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product UsersTotal
< 12 years426
12 years8816
13-15 years121325
16+ years336
Timeline Follow Back (TLFB)- Cigarettes
Timeline Follow Back (TLFB)- Cigarettes(cigarettes per day)Experimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product UsersTotal
Mean19.95 ± 7.7717.71 ± 0.7618.83 ± 4.26
ETM Budget
ETM Budget(dollars per week)Experimental: Exclusive Cigarette SmokersExperimental: Dual Cigarette/ Nicotine Vaping Product UsersTotal
Mean53.10 ± 25.071.5 ± 28.262.3 ± 26.6

6 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Fralin Biomedical Research Institute at VTC
    Roanoke, Virginia 24016, United States
09

References and documents

Study documents

  • Protocol, analysis plan and consent form · May 30, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — The study team will share de-identified data upon request.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06001840
Lead sponsor
Virginia Polytechnic Institute and State University
Collaborators
Medical University of South Carolina
Responsible party
Roberta Freitas-Lemos (Professor, Virginia Polytechnic Institute and State University) — Principal investigator
First posted
Aug 21, 2023
Start date
Jan 4, 2024
Primary completion
Feb 28, 2025
Completion
Mar 31, 2025
Results posted
Feb 10, 2026
Last update
Feb 10, 2026

Study contacts

Roberta Freitas-Lemos, Ph.D.
principal investigator · Fralin Biomedical Research Institute at Virginia Tech Carilion

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion